BioNexus Free Cash Flow Per Share vs Free Cash Flow Analysis

BGLC Stock

USD 0.24 0.01 4.00%

BioNexus Gene financial indicator trend analysis is way more than just evaluating BioNexus Gene Lab prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BioNexus Gene Lab is a good investment. Please check the relationship between BioNexus Gene Free Cash Flow Per Share and its Free Cash Flow accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNexus Gene Lab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Free Cash Flow Per Share vs Free Cash Flow

Free Cash Flow Per Share vs Free Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BioNexus Gene Lab Free Cash Flow Per Share account and Free Cash Flow. At this time, the significance of the direction appears to have almost identical trend.

The correlation between BioNexus Gene's Free Cash Flow Per Share and Free Cash Flow is 0.96. Overlapping area represents the amount of variation of Free Cash Flow Per Share that can explain the historical movement of Free Cash Flow in the same time period over historical financial statements of BioNexus Gene Lab, assuming nothing else is changed. The correlation between historical values of BioNexus Gene's Free Cash Flow Per Share and Free Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Per Share of BioNexus Gene Lab are associated (or correlated) with its Free Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow has no effect on the direction of Free Cash Flow Per Share i.e., BioNexus Gene's Free Cash Flow Per Share and Free Cash Flow go up and down completely randomly.

Correlation Coefficient

0.96

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Free Cash Flow Per Share

The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Most indicators from BioNexus Gene's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioNexus Gene Lab current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNexus Gene Lab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

At present, BioNexus Gene's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Issuance Of Capital Stock is expected to grow to about 6 M, whereas Enterprise Value Over EBITDA is forecasted to decline to (1.11).

	2021	2022	2023	2024 (projected)
Gross Profit	2.2M	1.3M	1.3M	1.2M
Total Revenue	13.4M	10.9M	9.8M	8.4M

Gross Profit Total Revenue

BioNexus Gene fundamental ratios Correlations

	Total Current Liabilities	Net Tangible Assets	Retained Earnings	Other Stockholder Equity	Total Current Assets	Common Stock	Other Current Liab	Other Liab	Accounts Payable	Net Receivables	Inventory	Property Plant Equipment	Total Assets	Short Long Term Debt Total	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Total Liab	Net Invested Capital	Long Term Investments
Total Current Liabilities		0.84	0.24	-0.7	0.93	0.79	-0.65	0.53	0.53	0.92	0.91	0.9	0.89	0.41	0.84	0.93	-0.54	0.52	0.83	0.52	0.71	0.45	0.41	0.96	0.84	0.57
Net Tangible Assets	0.84		-0.11	-0.7	0.94	0.9	-0.78	0.86	0.59	0.73	0.93	0.92	0.96	0.45	0.96	0.96	-0.82	0.81	0.96	0.81	0.93	0.65	0.45	0.89	0.96	0.9
Retained Earnings	0.24	-0.11		0.01	0.06	-0.15	-0.03	-0.24	0.08	0.54	0.17	0.11	0.0	-0.58	-0.08	0.09	0.62	-0.63	-0.06	-0.63	-0.07	-0.59	-0.58	0.2	-0.08	-0.42
Other Stockholder Equity	-0.7	-0.7	0.01		-0.71	-0.86	0.87	-0.49	-0.82	-0.54	-0.62	-0.64	-0.62	-0.28	-0.6	-0.64	0.44	-0.43	-0.62	-0.43	-0.62	-0.28	-0.28	-0.62	-0.6	-0.53
Total Current Assets	0.93	0.94	0.06	-0.71		0.92	-0.77	0.71	0.6	0.84	0.97	0.99	0.98	0.5	0.97	0.98	-0.7	0.68	0.96	0.68	0.88	0.64	0.5	0.94	0.97	0.75
Common Stock	0.79	0.9	-0.15	-0.86	0.92		-0.85	0.73	0.7	0.62	0.84	0.89	0.88	0.52	0.9	0.86	-0.73	0.71	0.9	0.71	0.88	0.67	0.52	0.78	0.9	0.78
Other Current Liab	-0.65	-0.78	-0.03	0.87	-0.77	-0.85		-0.54	-0.95	-0.61	-0.7	-0.72	-0.69	-0.32	-0.67	-0.72	0.48	-0.47	-0.69	-0.47	-0.7	-0.3	-0.32	-0.7	-0.67	-0.57
Other Liab	0.53	0.86	-0.24	-0.49	0.71	0.73	-0.54		0.25	0.42	0.75	0.71	0.78	0.19	0.83	0.74	-0.8	0.79	0.85	0.79	0.93	0.61	0.19	0.59	0.83	0.95
Accounts Payable	0.53	0.59	0.08	-0.82	0.6	0.7	-0.95	0.25		0.52	0.5	0.54	0.5	0.31	0.45	0.54	-0.28	0.28	0.46	0.28	0.44	0.13	0.31	0.58	0.45	0.32
Net Receivables	0.92	0.73	0.54	-0.54	0.84	0.62	-0.61	0.42	0.52		0.88	0.85	0.81	0.16	0.73	0.87	-0.29	0.27	0.73	0.27	0.64	0.21	0.16	0.93	0.73	0.4
Inventory	0.91	0.93	0.17	-0.62	0.97	0.84	-0.7	0.75	0.5	0.88		0.97	0.97	0.38	0.95	0.98	-0.65	0.63	0.94	0.63	0.89	0.55	0.38	0.94	0.95	0.73
Property Plant Equipment	0.9	0.92	0.11	-0.64	0.99	0.89	-0.72	0.71	0.54	0.85	0.97		0.99	0.45	0.97	0.98	-0.67	0.64	0.97	0.64	0.9	0.64	0.45	0.94	0.97	0.74
Total Assets	0.89	0.96	0.0	-0.62	0.98	0.88	-0.69	0.78	0.5	0.81	0.97	0.99		0.5	0.99	0.99	-0.77	0.75	0.98	0.75	0.91	0.7	0.5	0.94	0.99	0.82
Short Long Term Debt Total	0.41	0.45	-0.58	-0.28	0.5	0.52	-0.32	0.19	0.31	0.16	0.38	0.45	0.5		0.51	0.45	-0.69	0.68	0.44	0.68	0.29	0.77	1.0	0.44	0.51	0.4
Total Stockholder Equity	0.84	0.96	-0.08	-0.6	0.97	0.9	-0.67	0.83	0.45	0.73	0.95	0.97	0.99	0.51		0.97	-0.81	0.79	0.99	0.79	0.94	0.76	0.51	0.88	1.0	0.86
Property Plant And Equipment Net	0.93	0.96	0.09	-0.64	0.98	0.86	-0.72	0.74	0.54	0.87	0.98	0.98	0.99	0.45	0.97		-0.71	0.69	0.96	0.69	0.89	0.61	0.45	0.97	0.97	0.78
Net Debt	-0.54	-0.82	0.62	0.44	-0.7	-0.73	0.48	-0.8	-0.28	-0.29	-0.65	-0.67	-0.77	-0.69	-0.81	-0.71		-1.0	-0.79	-1.0	-0.75	-0.89	-0.69	-0.6	-0.81	-0.92
Cash	0.52	0.81	-0.63	-0.43	0.68	0.71	-0.47	0.79	0.28	0.27	0.63	0.64	0.75	0.68	0.79	0.69	-1.0		0.77	1.0	0.73	0.86	0.68	0.59	0.79	0.92
Non Current Assets Total	0.83	0.96	-0.06	-0.62	0.96	0.9	-0.69	0.85	0.46	0.73	0.94	0.97	0.98	0.44	0.99	0.96	-0.79	0.77		0.77	0.96	0.72	0.44	0.87	0.99	0.88
Cash And Short Term Investments	0.52	0.81	-0.63	-0.43	0.68	0.71	-0.47	0.79	0.28	0.27	0.63	0.64	0.75	0.68	0.79	0.69	-1.0	1.0	0.77		0.73	0.86	0.68	0.59	0.79	0.92
Common Stock Shares Outstanding	0.71	0.93	-0.07	-0.62	0.88	0.88	-0.7	0.93	0.44	0.64	0.89	0.9	0.91	0.29	0.94	0.89	-0.75	0.73	0.96	0.73		0.63	0.29	0.76	0.94	0.9
Non Current Liabilities Total	0.45	0.65	-0.59	-0.28	0.64	0.67	-0.3	0.61	0.13	0.21	0.55	0.64	0.7	0.77	0.76	0.61	-0.89	0.86	0.72	0.86	0.63		0.77	0.49	0.76	0.75
Capital Lease Obligations	0.41	0.45	-0.58	-0.28	0.5	0.52	-0.32	0.19	0.31	0.16	0.38	0.45	0.5	1.0	0.51	0.45	-0.69	0.68	0.44	0.68	0.29	0.77		0.44	0.51	0.4
Total Liab	0.96	0.89	0.2	-0.62	0.94	0.78	-0.7	0.59	0.58	0.93	0.94	0.94	0.94	0.44	0.88	0.97	-0.6	0.59	0.87	0.59	0.76	0.49	0.44		0.88	0.64
Net Invested Capital	0.84	0.96	-0.08	-0.6	0.97	0.9	-0.67	0.83	0.45	0.73	0.95	0.97	0.99	0.51	1.0	0.97	-0.81	0.79	0.99	0.79	0.94	0.76	0.51	0.88		0.86
Long Term Investments	0.57	0.9	-0.42	-0.53	0.75	0.78	-0.57	0.95	0.32	0.4	0.73	0.74	0.82	0.4	0.86	0.78	-0.92	0.92	0.88	0.92	0.9	0.75	0.4	0.64	0.86

Click cells to compare fundamentals

BioNexus Gene Account Relationship Matchups

BioNexus Gene fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Current Liabilities	51.6K	3.4M	2.3M	2.0M	1.6M	1.5M
Net Tangible Assets	1.5M	1.1M	6.7M	7.2M	8.3M	8.7M
Retained Earnings	(333.3K)	760.8K	1.5M	1.2M	(1.8M)	(1.8M)
Total Current Assets	882.6K	8.0M	7.1M	6.0M	8.0M	4.5M
Common Stock	6.6M	6.5M	10.8M	10.9M	17.2M	9.4M
Other Current Liab	19.4K	50.1K	32.3K	103.4K	194.1K	169.0K
Net Receivables	15.9K	4.0M	3.4M	2.9M	857.3K	814.4K
Inventory	7.6K	1.2M	1.5M	977.8K	1.1M	765.1K
Property Plant Equipment	341.8K	336.5K	1.8M	1.6M	1.9M	961.7K
Total Assets	1.2M	10.1M	9.6M	8.7M	11.4M	7.8M
Short Long Term Debt Total	89.4K	123.4K	76.9K	56.8K	133.4K	103.0K
Total Stockholder Equity	1.1M	6.7M	7.2M	6.7M	9.7M	6.0M
Property Plant And Equipment Net	336.5K	1.8M	1.7M	1.6M	1.7M	1.4M
Net Debt	(769.6K)	(2.7M)	(2.0M)	(2.1M)	(5.8M)	(5.5M)
Cash	859.1K	2.8M	2.1M	2.1M	5.9M	6.2M
Non Current Assets Total	348.7K	2.1M	2.4M	2.7M	3.4M	2.1M
Cash And Short Term Investments	859.1K	2.8M	2.1M	2.1M	5.9M	6.2M
Common Stock Shares Outstanding	7.2M	8.6M	14.3M	14.4M	15.9M	12.1M
Liabilities And Stockholders Equity	1.2M	10.1M	9.6M	8.7M	11.4M	7.8M
Non Current Liabilities Total	57.3K	79.5K	65.9K	71.1K	111.0K	82.9K
Capital Lease Obligations	89.4K	123.4K	76.9K	56.8K	133.4K	103.0K
Total Liab	108.9K	3.5M	2.4M	2.1M	1.7M	1.8M
Net Invested Capital	1.1M	6.7M	7.2M	6.7M	9.7M	6.0M
Long Term Investments	12.2K	281.7K	749.0K	1.2M	1.7M	1.8M
Accumulated Other Comprehensive Income	(17.1K)	133.7K	(100.3K)	(409.1K)	(677.3K)	(643.4K)
Net Working Capital	831.0K	4.6M	4.8M	4.0M	6.4M	4.0M
Short Term Debt	32.1K	91.5K	79.0K	16.6K	34.6K	50.0K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether BioNexus Gene Lab offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNexus Gene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bionexus Gene Lab Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bionexus Gene Lab Stock:

How To Invest In BioNexus

Details

Is BioNexus Stock a good investment?

Details

What is BioNexus Gene's Net Worth?

Details

Largest Specialty Chemicals Companies

View

Largest Basic Materials Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNexus Gene Lab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Is Specialty Chemicals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNexus Gene. If investors know BioNexus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNexus Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.95)

Earnings Share

(0.06)

Revenue Per Share

0.526

Quarterly Revenue Growth

(0.23)

Return On Assets

(0.10)

The market value of BioNexus Gene Lab is measured differently than its book value, which is the value of BioNexus that is recorded on the company's balance sheet. Investors also form their own opinion of BioNexus Gene's value that differs from its market value or its book value, called intrinsic value, which is BioNexus Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNexus Gene's market value can be influenced by many factors that don't directly affect BioNexus Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between BioNexus Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNexus Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNexus Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

BioNexus Free Cash Flow Per Share vs Free Cash Flow Analysis

Free Cash Flow Per Share vs Free Cash Flow

Free Cash Flow Per Share vs Free Cash Flow Correlation Analysis

Correlation Coefficient

Free Cash Flow Per Share

Free Cash Flow

BioNexus Gene fundamental ratios Correlations

BioNexus Gene Account Relationship Matchups

High Positive Relationship

High Negative Relationship

BioNexus Gene fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Capital Lease Obligations	+ 1.0	Short Long Term Debt Total
Net Invested Capital	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Cash
Property Plant Equipment	+ 0.99	Total Current Assets
Total Assets	+ 0.99	Property Plant Equipment
Total Stockholder Equity	+ 0.99	Total Assets

Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Accounts Payable	- 0.95	Other Current Liab
Long Term Investments	- 0.92	Net Debt
Non Current Liabilities Total	- 0.89	Net Debt
Common Stock	- 0.86	Other Stockholder Equity